About 通用幹細胞股份有限公司
通用幹細胞股份有限公司 is a company based in Taichung (Taiwan) founded in 2022. 通用幹細胞股份有限公司 offers products and services including Cell Culture Medium and Closed Cell Culture System.
- Headquarter Taichung, Taiwan
- Stage Public
- SectorsHealthcare
- Website dgsc.com.tw
- Social LinkedIn
- Legal Name Duogenic Stemcells Corporation
- Annual Revenue$20.69 M71.7as on Dec 31, 2025
- Net Profit-$26.38 M57.16as on Dec 31, 2025
- EBITDA-$20.18 M62.44as on Dec 31, 2025
Associated legal entities of 通用幹細胞股份有限公司
通用幹細胞股份有限公司 operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of 通用幹細胞股份有限公司
通用幹細胞股份有限公司 offers a comprehensive portfolio of products and services, including Cell Culture Medium and Closed Cell Culture System.
Cell culture media are provided by DuoGenic StemCells for cultivating human cells in 2D and 3D environments, with these media being certified and suitable for research and clinical applications
A closed cell culture system is offered by DuoGenic StemCells using bags for cell growth, which is intended to lower production costs and support the expansion of cell therapy
IPO & Listings of 通用幹細胞股份有限公司
通用幹細胞股份有限公司 is a publicly listed company on the TPEX with ticker symbol 7607 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 May 2023
- Listed onTT: 7607
- Listed entityDuoGenic StemCells Corporation
- Exchange sectorHealth technology
- ISINTW0007607004
- Share price8.43 TWD (-12.19% on the day) · 2026-10-08
- Market capitalisation308,984,790.00 TWD
- EPS (diluted, trailing year)-0.98 TWD
- Volume (last session)165,479
Financials of 通用幹細胞股份有限公司
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 20.7M TWD | -26.4M TWD | -20.2M TWD |
| 2024 | 12.1M TWD | -61.6M TWD | -53.7M TWD |
| 2023 | 13.7M TWD | -45.2M TWD | -37.9M TWD |
| 2022 | 6.9M TWD | -34.0M TWD | -28.1M TWD |
| 2021 | 2.3M TWD | -22.0M TWD | -20.5M TWD |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for 通用幹細胞股份有限公司
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of 通用幹細胞股份有限公司
Websites that share an audience with 通用幹細胞股份有限公司 (dgsc.com.tw).
Websites whose visitors overlap most with 通用幹細胞股份有限公司. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
kaiwill.com.tw | kaiwill.com.tw | 100% | – | – | – |
acmemach.com.tw | acmemach.com.tw | 98% | – | – | – |
hunkun.com.tw | hunkun.com.tw | 96% | – | – | – |
enzyvillage.com | enzyvillage.com | 88% | – | #11,272,229 | – |
li-cai.com.tw | li-cai.com.tw | 84% | – | #7,171,473 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for 通用幹細胞股份有限公司
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to 通用幹細胞股份有限公司
10 companies that operate in the same segment as 通用幹細胞股份有限公司 (Clinical Trials & Research Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 617.6 M | – | – | |
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | – | 22 | |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | 2004 | Ahmedabad, Gujarat, India | – | USD 50.52 M | 902 | |
Generic injectables for oncology and anesthesiology are manufactured. | 1989 | Hyderabad, Telangana, India | – | USD 4.22 M | 228 | |
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | – | 25 | |
Laboratory focused on biotechnology & molecule research services | 2018 | Cambridge, Massachusetts, United States | USD 32.68 M | – | – | |
Laboratory delivers discovery & research in nuclear and particle physics | 1947 | United States | – | – | 2,436 | |
Research and manufacturing of hemp products are conducted by BRC. | 2017 | Monterey, California, United States | USD 25.26 M | – | 16 | |
Genome sequencing studies are conducted for medical research purposes. | 2020 | Cambridge, Cambridgeshire, United Kingdom | USD 11.26 M | – | 12 | |
Novel immunotherapy therapeutic targets are discovered through laboratory research. | 2019 | Branford, Connecticut, United States | USD 92 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 通用幹細胞股份有限公司
通用幹細胞股份有限公司 was founded in 2022.
通用幹細胞股份有限公司 is headquartered in Taichung, Taiwan.
通用麵細胞股份有限公司 was founded in 2022 and is based in Taichung, Taiwan. Operations are managed from this location, with an online presence maintained through the domain dgsc.com.tw. The company functions as a limited liability entity, though specific sectors or services are not detailed in available records. Focus is placed on standard corporate activities in the Taiwanese market.
通用幹細胞股份有限公司 offers Cell Culture Medium and Closed Cell Culture System.
Yes, 通用幹細胞股份有限公司 is publicly traded on TPEX under the ticker symbol 7607.
通用幹細胞股份有限公司 operates through ,.